Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer

Bibliographic Data

ID15466653
AuthorsJaya Bagaria (0000-0003-0211-7803, Gachon University), Kyung-Ok Kim (0000-0001-5657-3842, Gachon University Gil Medical Center), Eva Bagyinszky (0000-0002-0487-8668, Gachon University), Seong Soo A An (0000-0002-8123-6183, Gachon University, corresponding author), Jeong‐Heum Baek (0000-0001-9124-8041, Gachon University, corresponding author)
Year2022
Volume19
Issue7
Pages4008-4008
Publication date2022-03-28
Open AccessYes
TypeARTICLE
VenueInternational Journal of Environmental Research and Public Health (JOURNAL)
Journal identifiersISSN: 1661-7827 • E-ISSN: 1660-4601
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph19074008
PMID35409691
OpenAlexW4220786509
LanguageEN
References cited43

Background: Neoadjuvant chemoradiotherapy (nCRT) prior to surgery is considered standard therapy for locally advanced rectal cancer. Unfortunately, most patients with rectal cancer are resistant to radiotherapy. This might be a genetic cause. The role of certain rectal cancer-causing genes has not been completely elucidated. This study aims to investigate the genes responsible for locally advanced rectal cancer patients not reacting to radiotherapy. Methods: Whole exome sequencing of the DNA samples was performed on the samples. Bioinformatic analysis on the subjects was established. Individual genetic information was screened to identify differently expressed genes that more frequently appeared in non-complete response (NCR) compared to complete response (CR) patients after nCRT. All variations were verified by Sanger sequencing. Results: Genotyping information and pathway analyses of the samples indicated genes such as FLCN, CALML5, and ANTXR1 to be commonly mutated in CR group, whereas genes such as GALNTL14, CNKSR1, ACD, and CUL3 were more commonly mutated in the NCR group. Chi-square test revealed some significant variants (<0.05) such as rs3744124 (FLCN), rs28365986 (ANTXR1), rs10904516 (CALML5), rs3738952 (CUL3), rs13394 and rs2293013 (PIH1D1), rs2274531 (GPA33), rs4963048 (BRSK2), rs17883366 (IL3RA), rs2297575 (PSMD5), rs2288101 (GALNT14), and rs11954652 (DCTN4). Conclusion: Identifying an array of genes that separate NCRs from CRs would lead to finding genetic biomarkers for early detection of rectal cancer patients that are resistant to nCRT. A further investigation to validate the significance of genetic biomarkers to segregate NCRs from CRs should be performed with a larger CRC dataset. Protein expression levels, as well as transcriptomic analysis, would also help us understand the mechanism of how these genes could play a role in preventing radiation therapy to patients. This would be essential to prevent redundant radiation therapy

Cancer · Chemotherapy · Colorectal cancer · Complete response · Inflammation · Inflammatory response · Neoadjuvant therapy · Colorectal Cancer Surgical Treatments · Colorectal Cancer Treatments and Studies · Genetic factors in colorectal cancer · Medicine · Internal Medicine · Oncology

  • Global Cancer Statistics 2020

    Open Access•Hyuna Sung, Adalberto M Filho et al.•CA: A Cancer Journal for Clinicians•2021

  • Global cancer statistics 2018

    Open Access•Francesca Bray, Freddie Bray et al.•CA: A Cancer Journal for Clinicians•2018

Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae